US2021260100A1PendingUtilityA1

Glucocerebroside treatment of disease

67
Assignee: ENZO THERAPEUTICS INCPriority: Feb 27, 2003Filed: Feb 10, 2021Published: Aug 26, 2021
Est. expiryFeb 27, 2023(expired)· nominal 20-yr term from priority
Inventors:Yaron IlanMaya MargalitAri Zimran
A61K 35/17A61K 35/15A61P 35/00A61K 31/00A61K 38/1709A61K 31/7004A61P 31/12A61K 31/7032A61K 31/70A61P 17/00A61K 31/739A61P 9/10A61P 31/18A61P 11/00A61K 38/00A61P 31/14A61P 31/00A61P 37/02A61P 1/16A61P 19/00A61P 7/00A61P 31/04A61P 1/04A61P 3/00A61K 31/7028A61P 29/00A61P 37/04A61P 31/20A61P 27/02A61P 9/00A61P 5/00A61P 25/28A61P 3/10A61P 1/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for the treatment of immune mediated or immune related diseases or disorders, infectious diseases, metabolic disorders and cancer in mammalian subjects. This method comprises the administration of a naturally occurring, mammalian intermediary metabolite or T cell receptor ligand, preferably a glucosylceramide, to a mammalian subject. In a preferred embodiment, such mammalian subjects are human beings.

Claims

exact text as granted — not AI-modified
1 . A method for improving glucose tolerance in a mammal, comprising:
 administering to a mammalian subject in need of increased glucose tolerance a pharmaceutical composition comprising an amount of glucocerebroside effective to increase glucose tolerance in the mammal, wherein as a result of said administration glucose tolerance in the mammal is increased.   
     
     
         2 . The method of  claim 1 , wherein the mammalian subject is a human subject. 
     
     
         3 . The method of  claim 1 , wherein said administering step comprises parenteral administration of said pharmaceutical composition. 
     
     
         4 . The method of  claim 3 , wherein the mammalian subject is a human subject. 
     
     
         5 . The method of  claim 1 , wherein said administering step comprises intravenous, intraperitoneal, or subcutaneous administration of said pharmaceutical composition. 
     
     
         6 . The method of  claim 5 , wherein the mammalian subject is a human subject. 
     
     
         7 . The method of  claim 1 , wherein said administering step comprises enteral administration of said pharmaceutical composition. 
     
     
         8 . The method of  claim 7 , wherein the mammalian subject is a human subject. 
     
     
         9 . The method of  claim 1 , wherein said administering step comprises oral administration of said pharmaceutical composition. 
     
     
         10 . The method of  claim 9 , wherein the mammalian subject is a human subject.

Join the waitlist — get patent alerts

Track US2021260100A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.